Medicare Pharmacy Benefit Managers Insulin Costs Medication Costs Price Increases Rytelo Monopolies Net Prices Weight-loss Drugs U.S. Senate Committee Government Regulations GLP-1 Drugs Market Manipulation Patient Impact Diabetes Medication Negotiation Medications Generic Drugs Medicare Negotiations 340B Program Negotiations Pharmacy-Benefit Managers Diabetes Medications Access to Medication Toxoplasmosis Treatment Tariffs Leqembi Novo Nordisk Import Policies Insulin Price Controls Factors Public Health Funding Diabetes Treatments International Price Discrepancy Value-based Pricing High Drug Costs Government Regulation Weight-Loss Drugs Asthma Inhalers Diabetes Treatment GLP-1s Patient Access Research and Development Patient Savings Affordability Challenges Semaglutide Drugs GLP-1 Agonists Investigations Diabetes and Obesity Drugs Regulatory Actions Rare Diseases United States Compounded Medications List Price Diabetes Drugs Obesity Drugs